Gliosarcoma

8 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Gliosarcoma
Treatment and conditionWhere it standsTrials
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1